arsenic trioxide has been researched along with s 1033 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hadden, MK; Wen, J | 1 |
| Du, Y; Fang, H; Xia, Y; Zhang, J | 1 |
2 review(s) available for arsenic trioxide and s 1033
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Medulloblastoma drugs in development: Current leads, trials and drawbacks.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cerebellar Neoplasms; Humans; Medulloblastoma; Protein Kinase Inhibitors | 2021 |
1 other study(ies) available for arsenic trioxide and s 1033
| Article | Year |
|---|---|
Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Endoplasmic Reticulum Stress; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Time Factors; Treatment Outcome | 2013 |